Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

Jean L. Koff, MD, MS
Published: Thursday, Jan 16, 2020



Jean L. Koff, MD, MS, assistant professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, discusses systemic therapies in follicular lymphoma.

There are many treatment options for patients with newly diagnosed or relapsed/refractory follicular lymphoma, explains Koff. Patient-related factors such as disease burden and personal preference may help guide treatment selection.

For example, the combination of lenalidomide (Revlimid) and rituximab (Rituxan; R2) is approved for patients with previously treated follicular lymphoma and marginal zone lymphoma.

Additional research regarding proper sequencing and patient selection will provide insight on optimal treatment approaches, concludes Koff.
SELECTED
LANGUAGE


Jean L. Koff, MD, MS, assistant professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, discusses systemic therapies in follicular lymphoma.

There are many treatment options for patients with newly diagnosed or relapsed/refractory follicular lymphoma, explains Koff. Patient-related factors such as disease burden and personal preference may help guide treatment selection.

For example, the combination of lenalidomide (Revlimid) and rituximab (Rituxan; R2) is approved for patients with previously treated follicular lymphoma and marginal zone lymphoma.

Additional research regarding proper sequencing and patient selection will provide insight on optimal treatment approaches, concludes Koff.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x